Dimitrios Mougiakakos

14.9k total citations · 5 hit papers
144 papers, 7.0k citations indexed

About

Dimitrios Mougiakakos is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Dimitrios Mougiakakos has authored 144 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Immunology, 56 papers in Oncology and 41 papers in Molecular Biology. Recurrent topics in Dimitrios Mougiakakos's work include Immune Cell Function and Interaction (49 papers), CAR-T cell therapy research (36 papers) and Immune cells in cancer (25 papers). Dimitrios Mougiakakos is often cited by papers focused on Immune Cell Function and Interaction (49 papers), CAR-T cell therapy research (36 papers) and Immune cells in cancer (25 papers). Dimitrios Mougiakakos collaborates with scholars based in Germany, Sweden and United States. Dimitrios Mougiakakos's co-authors include Katarina Le Blanc, Rolf Kiessling, C. Christian Johansson, Andréas Mackensen, Regina Jitschin, Martin Böttcher, Georg Schett, Isabel Poschke, Álvaro Lladser and Heiko Bruns and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

Dimitrios Mougiakakos

133 papers receiving 7.0k citations

Hit Papers

Multipotent mesenchymal stromal cells and the innate immu... 2012 2026 2016 2021 2012 2017 2017 2023 2024 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multipotent mesenchymal stromal cells and the innate immune system
    2012 768 citations Katarina Le Blanc, Dimitrios Mougiakakos profile →
  2. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer
    2017 729 citations Martin Boettcher, Dimitrios Mougiakakos et al. profile →
  3. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss
    2017 527 citations Martin Böttcher, Gerhard Krönke et al. profile →
  4. CAR T-cell therapy in autoimmune diseases
    2023 195 citations Georg Schett, Georg Schett et al. profile →
  5. Advancements and challenges in CAR T cell therapy in autoimmune diseases
    2024 85 citations Georg Schett, Fabian Müller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dimitrios Mougiakakos Germany 41 3.0k 2.6k 2.6k 1.3k 920 144 7.0k
Bo Tang China 31 1.9k 0.6× 2.4k 0.9× 2.5k 1.0× 572 0.4× 828 0.9× 114 6.5k
John Stagg Canada 47 4.4k 1.5× 5.0k 1.9× 3.3k 1.3× 1.3k 1.0× 954 1.0× 110 11.1k
Martha Quezado United States 38 1.9k 0.7× 2.1k 0.8× 1.8k 0.7× 802 0.6× 846 0.9× 153 6.8k
Karin Tarte France 50 3.5k 1.2× 2.8k 1.1× 2.6k 1.0× 2.2k 1.7× 743 0.8× 177 8.4k
Daniel H.D. Gray Australia 43 3.7k 1.3× 1.5k 0.6× 2.4k 0.9× 432 0.3× 552 0.6× 120 7.2k
Demin Wang United States 47 5.7k 1.9× 4.1k 1.6× 3.1k 1.2× 1.0k 0.8× 1.4k 1.5× 141 10.5k
Pipsa Saharinen Finland 36 1.1k 0.4× 2.6k 1.0× 3.5k 1.4× 793 0.6× 930 1.0× 69 6.5k
Seth B. Coffelt United Kingdom 34 4.6k 1.5× 3.6k 1.4× 2.7k 1.1× 634 0.5× 1.3k 1.5× 62 8.3k
Yangqiu Li China 36 2.2k 0.8× 2.2k 0.8× 2.2k 0.9× 445 0.3× 1.1k 1.1× 294 5.5k
Ursula Fearon Ireland 54 3.0k 1.0× 1.3k 0.5× 2.7k 1.1× 370 0.3× 1.0k 1.1× 166 8.4k

Countries citing papers authored by Dimitrios Mougiakakos

Since Specialization
Citations

This map shows the geographic impact of Dimitrios Mougiakakos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dimitrios Mougiakakos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dimitrios Mougiakakos more than expected).

Fields of papers citing papers by Dimitrios Mougiakakos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dimitrios Mougiakakos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dimitrios Mougiakakos. The network helps show where Dimitrios Mougiakakos may publish in the future.

Co-authorship network of co-authors of Dimitrios Mougiakakos

This figure shows the co-authorship network connecting the top 25 collaborators of Dimitrios Mougiakakos. A scholar is included among the top collaborators of Dimitrios Mougiakakos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dimitrios Mougiakakos. Dimitrios Mougiakakos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Keitel, Verena, Michael C. Kreißl, Tobias Goetze, et al.. (2025). CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement. Journal of Hepatology. 84(4). 829–836.
2.
Brünner, Franziska, Mathias Haenel, Igor Age Kos, et al.. (2025). Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Blood Advances. 10(7). 2186–2189.
3.
Faissner, Simon, Jeremias Motte, Christian Geis, et al.. (2024). Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proceedings of the National Academy of Sciences. 121(26). e2403227121–e2403227121. 25 indexed citations
4.
Schewe, Denis M., Fotini Vogiatzi, Christian Wichmann, et al.. (2024). Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade. HemaSphere. 8(2). e48–e48. 1 indexed citations
5.
Böttcher, Martin, Andrej Stoll, Simon Völkl, et al.. (2024). Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. 30(6). 628.e1–628.e9. 1 indexed citations
6.
Jacobs, Bénédikt, Christoph Kahl, Christian Koenecke, et al.. (2024). Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients. European Journal Of Haematology. 112(4). 641–649.
7.
Blache, Ulrich, Sandy Tretbar, Ulrike Koehl, Dimitrios Mougiakakos, & Stephan Fricke. (2023). CAR T cells for treating autoimmune diseases. RMD Open. 9(4). e002907–e002907. 50 indexed citations
8.
Surov, Alexey, Hans‐Jonas Meyer, Dimitrios Mougiakakos, et al.. (2023). CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas. European Radiology. 34(2). 790–796. 3 indexed citations
9.
Saul, Domenica, Manuela Krumbholz, Romy Loschinski, et al.. (2023). Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment. BMC Cancer. 23(1). 1153–1153. 2 indexed citations
10.
11.
Müller, Fabian, Sebastian Boeltz, Simon Völkl, et al.. (2023). OP0141 LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - DATA FROM THE FIRST SEVEN PATIENTS. Annals of the Rheumatic Diseases. 82. 93–94. 11 indexed citations
12.
Krahmer, Natalie, Thomas Fischer, Dimitrios Mougiakakos, et al.. (2022). A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients. Leukemia. 37(2). 288–297. 10 indexed citations
13.
Frenz, Silke, María‐Belén Vídriales, Marcos González, et al.. (2021). Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 138(19). 1830–1842. 74 indexed citations
14.
Böttcher, Martin, Andrej Stoll, Romy Loschinski, et al.. (2020). Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling. Cancer Research. 80(17). 3663–3676. 49 indexed citations
15.
Böttcher, Martin, et al.. (2020). Linking Immunoevasion and Metabolic Reprogramming in B-Cell–Derived Lymphomas. Frontiers in Oncology. 10. 594782–594782. 22 indexed citations
16.
Schaffer, Stefanie, Simon Völkl, Katrin Peter, et al.. (2019). Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA. Molecular Cancer Therapeutics. 19(2). 409–419. 25 indexed citations
17.
Mougiakakos, Dimitrios, Domenica Saul, Martina Braun, et al.. (2017). CD33/CD3-Bispecific T-Cell Engaging (BiTE®) Antibody Constructs Efficiently Target Monocytic CD14+ hla-DRlow IDO+ aml-MDSCs. Blood. 130. 1363–1363. 2 indexed citations
18.
Mougiakakos, Dimitrios, Maciej Machaczka, Regina Jitschin, et al.. (2012). Treatment of Familial Hemophagocytic Lymphohistiocytosis with Third-Party Mesenchymal Stromal Cells. Stem Cells and Development. 21(17). 3147–3151. 15 indexed citations
19.
Poschke, Isabel, Dimitrios Mougiakakos, Johan Hansson, Giuseppe Masucci, & Rolf Kiessling. (2010). Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign. Cancer Research. 70(11). 4335–4345. 329 indexed citations
20.
Mimura, Kousaku, Takashi Ando, Isabel Poschke, et al.. (2010). T cell recognition of HLA‐A2 restricted tumor antigens is impaired by the oncogene HER2. International Journal of Cancer. 128(2). 390–401. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bo Tang Breakdown of academic impact, for papers by John Stagg Breakdown of academic impact, for papers by Martha Quezado Breakdown of academic impact, for papers by Karin Tarte Breakdown of academic impact, for papers by Daniel H.D. Gray Breakdown of academic impact, for papers by Demin Wang Breakdown of academic impact, for papers by Pipsa Saharinen Breakdown of academic impact, for papers by Seth B. Coffelt Breakdown of academic impact, for papers by Yangqiu Li Breakdown of academic impact, for papers by Ursula Fearon
Rankless by CCL
2026